A phase II study of the combination bortezomib (Velcade, PS-341), dexamethasone, and rituximab in patients with Waldenstroms macroglobulinemia

Trial Profile

A phase II study of the combination bortezomib (Velcade, PS-341), dexamethasone, and rituximab in patients with Waldenstroms macroglobulinemia

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2016

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Rituximab (Primary)
  • Indications Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 Mar 2016 According to ClinicalTrials.gov record,time frame for primary end point has been changed from 2 years to 33.2 months.
    • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 10 Nov 2009 Actual end date (Feb 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top